Sprouty2 (Spry2) reduces protein degradation by binding to c-CBL, thereby increasing the expression of epidermal growth factor receptor (EGFR), and it is a potential biomarker for predicting anti-EGFR response in colon cancer patients (eng et al., 2010). Here, CBL is linked to colonic neoplasm.